Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Stribild Included in Co-Pay and Assistance Programs

September 10, 2012

Gilead Sciences announced on September 7 that it has enhanced its co-pay and patient assistance programs, including the addition of Stribild, the recently approved single tablet regimen (STR).

Formerly know as "the Quad," Stribild is now part of Gilead's Advancing Access Program, making it available via a Patient Assistance Program (PAP) for people with an annual income of up to 500% Federal Poverty Level (FPL, which is $11,170 per individual), or $55,850 per year for one individual. Stribild will also be listed on the new universal PAP form issued by the Department of Health & Human Services (DHHS).

Gilead has also expanded co-pay assistance for Atripla and Complera and is including Stribild in a program that will now offer up to $400 per month in co-pays, up from $200 previously.

For more information, see the package insert, click here, or call 1-800-GILEAD-5 (1-800-445-3235).



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Positively Aware. It is a part of the publication Positively Aware. Visit Positively Aware's website to find out more about the publication.
 
See Also
More News on Stribild (Elvitegravir/Cobicistat/FTC/Tenofovir)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement